Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD)

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 43-60

  Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

secretase; Alzheimer's disease (AD); amyloid beta (A ) peptides; amyloidosis; beta amyloid cleavage enzyme 1 (BACE 1); beta amyloid precursor protein ( APP); chelation therapy; immunological strategies; neurodegenerative disease; presenilin 1 (PS1); secretase; statins

Indexed keywords

2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; AMYLOID BETA PROTEIN; AVASIMIBE; AZD 103; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BEXAROTENE; CHOLINESTERASE INHIBITOR; CTS 2166; DIMEBON; DONEPEZIL; FLUINDOSTATIN; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELISSA OFFICINALIS EXTRACT; MEMANTINE; MEVINOLIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NOOTROPIC AGENT; PRAVASTATIN; RIVASTIGMINE; SALVIA OFFICINALIS EXTRACT; SEMAGACESTAT; SIMVASTATIN; SOLANEZUMAB; TACRINE; TARENFLURBIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; AUTISM; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN EDEMA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHELATION THERAPY; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HEADACHE; HEALTH CARE NEED; HUMAN; HYPERPLASIA; IMMUNIZATION; IMMUNOPATHOLOGY; LIVER FAILURE; LIVER TOXICITY; LUNG DISEASE; MELISSA OFFICINALIS; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NYSTAGMUS; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; PROTEIN PROCESSING; SALVIA OFFICINALIS; SOCIOECONOMICS; SYSTEMIC LUPUS ERYTHEMATOSUS; TINNITUS; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

EID: 84858959323     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.672559     Document Type: Article

References (166)

1. Alzheimer Association: 2011 Alzheimer's Disease Facts and Figures statistical resource. Available from: http://www.alz. org/downloads/Facts- Figures-2011.pdf Compilation of AD-relevant facts and figures.
2. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer's disease: a European Task Force group. Lancet Neurol 2007;6:56-62 (Pubitemid 44880273)
3. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 1995;8:429-31 For neuroscience graduate student, neurologists and AD researchers a must read.
4. Lukiw WJ. One hundred years of Alzheimer's disease research: are we any closer to a cure? Aging Health 2007;3:279-82 (Pubitemid 46971133)
5. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 2006;9:151-3 What is wrong and what is right with the amyloid cascade hypothesis of AD. (Pubitemid 44253307)
6. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011;10:778-92
7. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712
8. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J Alzheimers Dis 2006;9:151-3 Comprehensive and critical review on the contribution of amyloid signaling to AD. (Pubitemid 44253307)
9. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060-5 Comprehensive evaluation of current approaches to AD therapeutics.
10. Esiri MM, Chance SA. Vulnerability to Alzheimer's pathology in neocortex: the roles of plasticity and columnar organization. J Alzheimers Dis 2006;9:79-89 (Pubitemid 44253301)
11. Cui JG, Hill JM, Zhao Y, Lukiw WJ. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Neuroreport 2007;18:115-19 Pathological factors in AD brain - spreading from association to primary sensory areas.
12. van de Pol LA, Korf ES, van der Flier WM, et al. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 2007;64:1023-8 (Pubitemid 47048004)
13. Marshall GA, Monserratt L, Harwood D, et al. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther 2011;3:31-4
14. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci 2005;25:10874-83 (Pubitemid 41692617)
15. Ewers M, Sperling RA, Klunk WE, et al. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011;34:430-42 An excellent and current review of the electronic imaging of AD brain neuropathology.
16. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-4 (Pubitemid 43739900)
17. Tomita T. At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch Pharmacol 2008;377:295-300 A thoughtful review of Ab42-lowering strategies for AD treatment.
18. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30:317-25 (Pubitemid 350307310)
19. Epis R, Marcello E, Gardoni F, Luca MD. Alpha, beta-and gamma-secretases in Alzheimer's disease. Front Biosci (Schol Ed) 2012;4:1126-50
20. Van Broeck B, Van Broeckhoven C, Kumar-Singh S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis 2007;4:349-65 (Pubitemid 47123462)
21. Dong J, Lu K, Lakdawala A, et al. Controlling amyloid growth in multiple dimensions. Amyloid 2006;13:206-15 (Pubitemid 44764460)
22. Li H, Wolfe MS, Selkoe DJ. Toward structural elucidation of the gamma-secretase complex. Structure 2009;17:326-34
23. Lukiw WJ. Docosahexaenoic acid and amyloid-beta peptide signaling in Alzheimer's disease. World Rev Nutr Diet 2009;99:55-70
24. Lukiw WJ, Bazan NG. Survival signaling in Alzheimer's disease. Biochem Soc Trans 2006;34:1277-82 A comprehensive review of DHA and NPD1 strategies for the treatment of AD.
25. Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 2006;1094:38-46 (Pubitemid 43927608)
26. Dube JB, Johansen CT, Hegele RA. Sortilin: an unusual suspect in cholesterol metabolism: from GWAS identification to in vivo biochemical analyses, sortilin has been identified as a novel mediator of human lipoprotein metabolism. Bioessays 2011;33:430-7
27. Zhao Y, Zhao B. Natural antioxidants in prevention and management of Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:794-808
28. Armstrong RA. Plaques and tangles and the pathogenesis of Alzheimer's disease. Folia Neuropathol 2006;44:1-11
29. Offe K, Dodson SE, Shoemaker JT, et al. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J Neurosci 2006;26:1596-603 (Pubitemid 43237030)
30. Available from: http://www.healthscout. com/animation/68/7/main. html#transcript www.knol.google.com/k/ ba pineuzumab -pfizer-j-j-elan-review#
31. Zhang H, Ma Q, Zhang YW, Xu H. Proteolytic processing of Alzheimer'sbeta-amyloid precursor protein. J Neurochem 2012;120:9-21
32. Zhou ZD, Chan CH, Ma QH, et al. The roles of amyloid precursor protein (APP) in neurogenesis: implications to pathogenesis and therapy of Alzheimer disease. Cell Adhes Migr 2011;5:280-92
33. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39:168-77 (Pubitemid 46184347)
34. Zhao Y, Cui JG, Lukiw WJ. Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells. Neuroreport 2007;18:1187-91 (Pubitemid 46988077)
35. Lukiw WJ, Pappolla M, Pelaez RP, Bazan NG. Alzheimer's disease-a dysfunction in cholesterol and lipid metabolism. Cell Mol Neurobiol 2005;25:475-83 (Pubitemid 41186260)
36. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-Amyloid and reverse deficits in AD mouse models. Science 2012. [Epub ahead of print]
37. Houacine J, Bolmont T, Aeschbach L, et al. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Abeta peptides. Neurobiol Aging 2012; Epub ahead of print
38. Carter C. Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and their relationships with herpes Simplex, C. Pneumoniae, other suspect pathogens, and the immune system. Int J Alzheimers Dis 2011;2011:501862
39. Carter CJ. Alzheimer's disease: a pathogenetic autoimmune disorder caused by herpes simplex in a gene-dependent manner. Int J Alzheimers Dis 2010;2010:140539
40. Castellani RJ, Smith MA. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. J Pathol 2011;224:147-52
41. Lee HG, Zhu X, Castellani RJ, et al. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther 2007;321:823-9 (Pubitemid 46762675)
42. Lee HG, Zhu X, Nunomura A, et al. Amyloid beta: the alternate hypothesis. Curr Alzheimer Res 2006;3:75-80
43. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 2004;1019:1-4 (Pubitemid 38951274)
44. Lukiw WJ, Cui JG, Yuan LY, et al. Acyclovir or Abeta42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. Neuroreport 2010;21:922-7
45. Wozniak MA, Frost AL, Preston CM, Itzhaki RF. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One 2011;6(10):e25152
46. Lukiw WJ. 100 years of Alzheimer's disease research: are we any closer to a cure? Aging Health 2007;3:279-82 Comprehensive overview review on progress in AD over the last 101 years.
47. Thal LJ. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20:S97-9 (Pubitemid 44265859)
48. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006;52:3-13 A candid overview review on progress in AD over the last 100 years.
49. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005;120:545-55 (Pubitemid 40269768)
50. Ferri CP, Prince M, Brayne C, Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-17 (Pubitemid 41797645)
51. Delrieu J, Piau A, Caillaud C, et al. Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy. CNS Drugs 2011;25:213-26
52. Lyketsos CG, Colenda CC, Beck C, et al. Task Force of American Association for Geriatric Psychiatry. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. Am J Geriatr Psychiatry 2006;14:561-72 (Pubitemid 44036480)
53. Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J Alzheimers Dis 2011. [Epub ahead of print]
54. van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009;5:237-47
55. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD00593
56. Salomone S, Caraci F, Leggio GM, et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease-modifying drugs. Br J Clin Pharmacol 2011. [Epub ahead of print]
57. Holzgrabe U, Kapkova P, Alptuzun V, et al. Targeting acetylcholin- esterase to treat neurodegeneration. Expert Opin Ther Targets 2007;11:161-79
58. Yanagisawa K. Newly approved drugs for Alzheimer disease: effectiveness and limitation. Brain Nerve 2011;63:863-8
59. Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs 2011;71:2031-65
60. Tanovice A, Alfaro V. Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia. Rev Neurol 2006;42:607-16 (Pubitemid 47378349)
61. Bordji K, Becerril-Ortega J, Buisson A. Synapses, NMDA receptor activity and neuronal Abeta production in Alzheimer's disease. Rev Neurosci 2011;22:285-94
62. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; and the Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21:136-43
63. Creeley CE, Wozniak DF, Nardi A, et al. Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 2008;29:153-67
64. Mount C, Downton C. Alzheimer's disease: progress or profit? Nat Med 2006;3:1280-4 A critical review on advancement, complexity and profiteering in AD treatment.
65. Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease. CNS Drugs 2007;21:177-8466.
66. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006(2):CD003154
67. Khairallah MI, Kassem LA. Alzheimer's disease: current status of etiopathogenesis and therapeutic strategies. Pak J Biol Sci 2011;14:257-72
68. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7; 60
69. Olkhanud PB, Mughal M, Ayukawa K, et al. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid beta-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 2012. [Epub ahead of print]
70. Grimm MO, Rothhaar TL, Hartmann T. The role of APP proteolytic processing in lipid metabolism. Exp Brain Res 2011. [Epub ahead of print]
71. Panza F, Frisardi V, Solfrizzi V, et al. Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 2012;4:213-38
72. Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 2012;8:135-49
73. Lukiw WJ. Emerging amyloid beta (Abeta) peptide modulators for the treatment of Alzheimer's disease (AD). Expert Opin Emerg Drugs 2008;13:255-71 (Pubitemid 351957348)
74. Hashimoto M, Hossain S. Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer's disease. J Pharmacol Sci 2011;116:150-62
75. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 2012;3:1-7
76. Leon H, Shibata MC, Sivakumaran S, et al. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ 2008;337:a2931
77. Mancuso C, Siciliano R, Barone E, Preziosi P. Natural substances and Alzheimer's disease: From preclinical studies to evidence based medicine. Biochim Biophys Acta 2011. [Epub ahead of print]
78. Mancuso C, Siciliano R, Barone E, et al. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin Investig Drugs 2011;20:1243-61
79. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010;23:518-23
80. Carlsson CM, Xu G, Wen Z, et al. Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study. Curr Alzheimer Res 2011. [Epub ahead of print]
81. Santos DB, Peres KC, Ribeiro RP, et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp Neurol 2011 [Epub ahead of print]
82. Gelosa P, Cimino M, Pignieri A, et al. The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag 2007;3:567-77 (Pubitemid 350104113)
83. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007;59:483-99 Critical review on the pleiotropic effects of statin apart from cholesterol down-regulation.
84. Parsons RB, Farrant JK, Price GC, et al. Regulation of the lipidation of beta-secretase by statins. Biochem Soc Trans 2007;35:577-82
85. Butterfield DA, Barone E, Di Domenico F, et al. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain. Int J Neuropsychopharmacol 2011;18:1-7
86. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 2006;23:111-22 The contribution of cholesterol to Ab generation and signaling in AD.
87. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 2012. [Epub ahead of print]
88. Ledesma MD, Dotti CG. Peripheral cholesterol, metabolic disorders and Alzheimer's disease. Front Biosci (Elite Ed) 2012;4:181-94
89. Wolozin B, Manger J, Bryant R, et al. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63-70 (Pubitemid 44015227)
90. Pac-Soo C, Lloyd DG, Vizcaychipi MP, Ma D. Statins: the role in the treatment and prevention of Alzheimer's neurodegeneration. J Alzheimers Dis 2011;27:1-10
91. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 2011;68:1239-44
92. Parri HR, Hernandez CM, Dineley KT. Research update: alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011;82:931-42
93. Burnett JR, Telford DE, Barrett PH, Huff MW. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. Biochim Biophys Acta 2005;1738:10-18
94. Yatskar L, Fisher EA, Schwartzbard A. Ezetimibe: rationale and role in the management of hypercholesterolemia. Clin Cardiol 2006;29:52-5 (Pubitemid 43235180)
95. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005;1:29-40 Early reports on the benefits of statins to AD treatment.
96. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008;70:1795-802 Review of large clinical trials examining effects of statins on AD markers. (Pubitemid 351653958)
97. Sparks DL. Alzheimer disease: statins in the treatment of Alzheimer disease. Nat Rev Neurol 2011;7:662-398.
98. Sabbagh MN, Sparks DL. Statins to treat Alzheimer's disease: an incomplete story. Expert Rev Neurother 2012;12:27-30 The ongoing story of statins as AD-relevant medications.
99. Garzone P, Koller M, Pastrak A, et al. Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimers Demen 2009;5:323
100. Huttunen HJ, Greco C, Kovacs DM. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett 2007;581:1688-92 (Pubitemid 46546584)
101. Aisen PS, Gauthier S, Vellas B, et al. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007;4:473-8 (Pubitemid 47416642)
102. Sabbagh MN. Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother 2009;7:167-85
103. Available from: http://www. medicalnewstoday.com/articles/75040. php www.myriad.com/
104. Imbimbo BP, Giardina GA. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem 2011;11:1555-70
105. Myriad website. Available from: http://www.myriad.com/alzheimers/ flurizan.php
106. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006;13:981-5 (Pubitemid 44284905)
107. Kim HG, Oh MS. Nutraceuticals and prevention of neurodegeneration herbal medicines for the prevention and treatment of Alzheimer's Disease. Curr Pharm Des 2012. [Epub ahead of print]
108. Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 2011;28:439-68
109. Roberts BR, Ryan TM, Bush AI, et al. The role of metallobiology and amyloid-beta peptides in Alzheimer's disease. J Neurochem 2012;120:149-66
110. Squitti R. Metals in Alzheimer's disease: a systemic perspective. Front Biosci 2012;17:451-72
111. Percy ME, Kruck TP, Pogue AI, Lukiw WJ. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. J Inorg Biochem 2011;105:1505-12
112. Kruck TP, Cui JG, Percy ME, Lukiw WJ. Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. Cell Mol Neurobiol 2004;24:443-59 Combinatorial use of antioxidants and chelators to neutralize neurotoxic metal effects on Ab peptide aggregation in AD and other neurodegenerative diseases. (Pubitemid 38988074)
113. Kawahara M, Kato-Negishi M. Link between Aluminum and the pathogenesis of Alzheimer's disease: the integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011;2011:276393 Multifactorial interactive events in AD.
114. Kruck TP, Percy ME, Lukiw WJ. Metal sulfate-mediated induction of pathogenic genes and repression by phenyl butyl nitrone and Feralex-G. Neuroreport 2008;19:245-9 Systematic analysis and the use of antioxidants and chelators in combination to neutralize neurotoxic metal effects in neurodegenerative disease.
115. Zhao Y, Calon F, Julien C, et al. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer's disease models. PLoS One 2011;6:e15816
116. Cole GM, Frautschy SA. DHA may prevent age-related dementia. J Nutr 2010;140:869-74
117. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005;115:2774-83 Potential benefits of DHA and DHA-derived NPD1 in the treatment of AD.
118. Serini S, Bizzarro A, Piccioni E, et al. EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer's patients. Curr Alzheimer Res 2012. [Epub ahead of print]
119. Lebbadi M, Julien C, Phivilay A, et al. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease. J Alzheimers Dis 2011;27:853-69
120. Amtul Z, Keet M, Wang L, et al. DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet? PLoS One 2011;6:e24094
121. Lukiw WJ. Cholesterol and -hydroxycholesterol trafficking in Alzheimer's disease. Expert Rev Neurother 2006;6:683-93 A comprehensive review on cholesterol signaling in AD brain and potential treatment using inhibitors of cholesterol synthesis.
122. Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4 A classical paper evaluating the cholesterol-Ab peptide connection. (Pubitemid 28249035)
123. Epis R, Marcello E, Gardoni F, Luca MD. Alpha, beta-and gammasecretases in Alzheimer's disease. Front Biosci (Schol Ed) 2012;4:1126-50
124. Ballard C, Khan Z, Clack H, Corbett A. Nonpharmacological treatment of Alzheimer disease. Can J Psychiatry 2011;56:589-95 Recent overview of potential non-drug AD-relevant formulations.
125. Saravanan P, Davidson NC. Fish oil and arrhythmias. Pro-arrhythmic effects of fish oils. BMJ 2009;338:b393
126. Burgener SC, Buettner L, Coen Buckwalter K, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease (AD). J Nutr Health Aging 2008;12:18-21 Non-pharmaceutical and nutritional approaches to AD management. (Pubitemid 351156010)
127. Burns A, O'Brien J; BAP Dementia Consensus groupAuriacombe S, British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55 (Pubitemid 44622739)
128. Sparks DL, Connor DJ, Sabbagh MN, et al. Circulating cholesterol levels, apolipoprotein E genotype and dementiaseverity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006;185:3-7 (Pubitemid 44015218)
129. Available from: www.clinicaltrials.gov www.alzforum.org/drg/drc/default. asp
130. Li L, Cao D, Kim H, et al. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006;60:729-39 (Pubitemid 46061359)
131. Hoglund K, Wiklund O, Vanderstichel H, et al. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004;61:333-7 (Pubitemid 38327348)
132. Wu TY, Chen CP, Jinn TR. Traditional Chinese medicines and Alzheimer's disease. Taiwan J Obstet Gynecol 2011;50:131-5 Potential benefits of Chinese traditional and ethnobotanical medicines to treat AD.
133. Chakrabortee S, Liu Y, Zhang L, et al. Macromolecular and small molecule modulation of intracellular Abeta42 aggregation and associated toxicity. Biochem J 2011. [Epub ahead of print]
134. Kumar V. Potential medicinal plants for CNS disorders: an overview. Phytother Res 2006;20:1023-35 Overview of potential AD-relevant natural medications. (Pubitemid 44951704)
135. Steele M, Stuchbury G, Munch G. The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 2007;42:28-36 Non-pharmaceutical and dietary/nutritional approaches to AD treatment. (Pubitemid 44937827)
136. Adams M, Gmunder F, Hamburger M. Plants traditionally used in age related brain disorders-a survey of the ethnobotanical literature. J Ethnopharmacol 2007;113:363-81 Potential benefits of ethnobotanical medicines to AD treatment. (Pubitemid 47361572)
137. Kim HG, Oh MS. Nutraceuticals and prevention of neurodegeneration herbal medicines for the prevention and treatment of Alzheimer's Disease. Curr Pharm Des 2012. [Epub ahead of print] Potential benefits of ethnobotanical medicine for the treatment of AD.
138. Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatric Psychiatry 2010;18:928-39
139. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA 2011;108:3017-22
140. Butterfield DA, Barone E, Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 2011;64:180-6
141. Medical School, Harvard Health Newsletters. Disease-modifying drug fails in Alzheimer's study. Harv Ment Health Lett 2010;26:7-11
142. Green RC, Schneider LS, Amato DA, Tarenflurbil Phase III Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
143. Wan HI, Jacobsen JS, Rutkowski JL, Feuerstein GZ. Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: implication for future drug discovery and development for AD. Clin Transl Sci 2009;2:242-7
144. Wang J, Ferruzzi MG, Varghese M, et al. Preclinical study of dimebon on beta-amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 2011;6:7-11
145. Fisher Center for Alzheimer's Research Foundation 2011. ClinicalTrials.gov. Available from: www.ALZinfo.org http:// www.clinicaltrials. gov/ct2/results? term=alzheimer%27s+disease
146. Mancuso C, Siciliano R, Barone E, et al. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Expert Opin Investig Drugs 2011;20:1243-61
147. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007;18:297-300 First paper to report significant changes in micro RNA (miRNA) speciation in AD.
148. Lukiw WJ, Zhao Y, Cui JG. An NF-kB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008;283:31315-22 First paper to report a specific miRNA-mediated pathogenic mechanism in AD.
149. Sethi P, Lukiw WJ. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett 2009;459:100-4
150. Cui JG, Li YY, Zhao Y, et al. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by miRNA-146a and NF-kB in stressed human astroglial cells and in Alzheimer disease. J Biol Chem 2010;285:38951-60 Involvement of aberrant NF-kB signaling and the innate immune system in AD.
151. Holtzman JL. Are we prepared to deal with the Alzheimer's disease pandemic? Clin Pharmacol Ther 2010;88:563-5
152. Zhao Y, Cui JG, Lukiw WJ. Natural secretory products of human neural and microvessel endothelial cells: implications in pathogenic "spreading" and Alzheimer's disease. Mol Neurobiol 2006;34:181-92 Novel hypothesis on the pathological spreading of AD throughout the human brain.
153. Itil TM, Eralp E, Ahmed I, et al. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacol Bull 1998;34:391-7 (Pubitemid 28537965)
154. Fujiwara H, Iwasaki K, Furukawa K, et al. Uncaria rhynchophylla, a Chinese medicinal herb, has potent anti-aggregation effects on Alzheimer's beta-amyloid proteins. J Neurosci Res 2006;84:427-33 (Pubitemid 44126295)
155. Eubanks LM, Rogers CJ, Beuscher AE, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006;3:773-7 (Pubitemid 46087493)
156. da Rocha MD, Viegas FP, Campos HC, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disordersII: Alzheimer's disease. CNS Neurol Disord Drug Targets 2011;10:251-70 Current update on natural products and ethnobotanical approaches to successful AD treatment.
157. Aisen PS. Development of a disease-modifying treatment for Alzheimer's disease: alzhemed. Alzheimers Dement 2006;2:153-4 (Pubitemid 43843093)
158. Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7:102-11
159. Saumier D, Aisen PS, Gauthier S, et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J Nutr Health Aging 2009;13:370-2
160. Sato N, Shinohara M, Rakugi H, Morishita R. Dual effects of statins on Abeta metabolism: upregulation of the degradation of APP-CTF and Abeta clearance. Neurodegener Dis 2012. [Epub ahead of print]
161. Carlsson CM, Xu G, Wen Z, et al. Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study. Curr Alzheimer Res 2011. [Epub ahead of print]
162. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch Neurol 2011;68:1385-92
163. Bachurin S, Bukatina E, Lermontova N, et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001;939:425-35 (Pubitemid 32620096)
164. Hill JM, Zhao Y, Clement C, et al. HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling. Neuroreport 2009;20:1500-5
165. Hill JM, Gebhardt BM, Azcuy AM, et al. Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease? Med Hypotheses 2005;64:320-7 (Pubitemid 40022673)
166. McLaurin J, Cecal R, Kierstead ME, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-9 (Pubitemid 35373558)